| Jan'20 | Oct'19 | Jul'19 | Apr'19 | Jan'19 | Oct'18 | Jul'18 | Apr'18 | Jan'18 | Oct'17 |
|---|---|---|---|---|---|---|---|---|---|
Operating activities | |||||||||
Net Loss | |||||||||
-6,538 | -5,911 | -4,924 | 0 | 0 | 0 | - | - | 0 | 0 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Depreciation and amortization | |||||||||
1,858 | 1,816 | 1,779 | 0 | 0 | 0 | - | - | - | 0 |
Deferred income taxes | |||||||||
8 | 22 | -19 | -16 | 7 | -19 | 8,859 | 0 | 0 | 0 |
Interest income | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Net gain on sales of marketable securities | |||||||||
- | - | 330 | 0 | 0 | 0 | - | - | - | 0 |
Unrealized (gain) loss on investments - Hedge Funds | |||||||||
0 | 0 | - | - | - | - | - | - | - | - |
Provision for doubtful accounts | |||||||||
0 | 0 | - | - | - | - | - | - | - | - |
Non-cash compensation | |||||||||
611 | 436 | 372 | 0 | 0 | 0 | - | - | - | 0 |
Amortization of debt discount | |||||||||
0 | 0 | - | - | - | - | - | - | - | - |
Realized gain on disposal of bonus shares | |||||||||
- | - | - | - | - | - | 246 | 0 | 0 | 0 |
Change in assets and liabilities: | |||||||||
Trade accounts receivable | |||||||||
130 | 20 | 285 | 352 | 139 | 27 | 23 | 0 | 0 | 0 |
Prepaid expenses and other current assets | |||||||||
-281 | -194 | 86 | 285 | 384 | 327 | 258 | 0 | 0 | 0 |
Other assets | |||||||||
-319 | 1 | -275 | 411 | 408 | 459 | 586 | 0 | 0 | 0 |
Accounts payable and accrued expenses | |||||||||
-15 | 475 | 533 | -167 | 184 | -252 | -35 | 0 | 0 | 0 |
Due to Related Party | |||||||||
- | 446 | - | - | - | 433 | 2 | 0 | 0 | 0 |
Due to/from related parties | |||||||||
0 | 0 | - | - | - | - | - | - | - | - |
Other current liabilities | |||||||||
- | -3 | 3 | -7 | 44 | 9 | -10 | 0 | 0 | 0 |
Other liabilities | |||||||||
- | - | - | - | 0 | 0 | - | - | - | - |
Other liabilities | |||||||||
- | - | - | - | - | - | 118 | 0 | 0 | 0 |
Net cash used in operating activities | |||||||||
-4,133 | -3,344 | -3,132 | -3,283 | -2,755 | -2,510 | -1,815 | 0 | 0 | 0 |
Investing activities | |||||||||
Purchases of property and equipment | |||||||||
797 | 694 | 399 | 502 | 40 | 513 | 710 | 0 | 0 | 0 |
Proceeds from sale and maturity of marketable securities, net | |||||||||
- | - | 25,031 | 0 | 0 | 0 | - | - | - | 0 |
Purchase of marketable securities | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Investment in Rafael Pharmaceuticals | |||||||||
- | - | - | - | 56,021 | 10,151 | 151 | 0 | 0 | 0 |
Investment in Rafael Pharmaceuticals | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Net cash used in investing activities | |||||||||
-797 | -26,400 | -31,238 | -26,958 | -26,060 | -827 | 4,109 | 0 | 0 | 0 |
Financing activities | |||||||||
Proceeds from exercise of options | |||||||||
- | - | 190 | 0 | 0 | 0 | - | - | - | 0 |
Net cash (used in) provided by financing activities | |||||||||
- | - | 30,889 | 32,604 | 31,677 | 1,868 | 1,750 | 0 | 0 | 0 |
Effect of exchange rate changes on cash and cash equivalents | |||||||||
-263 | -342 | -298 | -5 | -107 | 30 | -3 | 0 | 0 | 0 |
Net decrease in cash and cash equivalents | |||||||||
-5,247 | 685 | -3,779 | 2,364 | 2,761 | -1,433 | 4,047 | 0 | 0 | 0 |
Supplemental Schedule of Non-Cash Investing and Financing Activities | |||||||||
Adoption effect of ASU 2016-01 | |||||||||
- | - | 39 | 0 | 0 | 0 | - | - | - | 0 |
Conversion of LipoMedix Bridge Note | |||||||||
0 | 0 | - | - | - | - | - | - | - | - |
Conversions of related party convertible notes payable and accrued interest | |||||||||
0 | 0 | - | - | - | - | - | - | - | - |